1. Home
  2. BUJA vs VSTM Comparison

BUJA vs VSTM Comparison

Compare BUJA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BUJA
  • VSTM
  • Stock Information
  • Founded
  • BUJA 2022
  • VSTM 2010
  • Country
  • BUJA Malaysia
  • VSTM United States
  • Employees
  • BUJA N/A
  • VSTM N/A
  • Industry
  • BUJA Blank Checks
  • VSTM Biotechnology: Pharmaceutical Preparations
  • Sector
  • BUJA Finance
  • VSTM Health Care
  • Exchange
  • BUJA Nasdaq
  • VSTM Nasdaq
  • Market Cap
  • BUJA N/A
  • VSTM 132.0M
  • IPO Year
  • BUJA 2023
  • VSTM 2012
  • Fundamental
  • Price
  • BUJA $10.96
  • VSTM $3.88
  • Analyst Decision
  • BUJA
  • VSTM Strong Buy
  • Analyst Count
  • BUJA 0
  • VSTM 8
  • Target Price
  • BUJA N/A
  • VSTM $14.57
  • AVG Volume (30 Days)
  • BUJA 2.7K
  • VSTM 1.1M
  • Earning Date
  • BUJA 01-01-0001
  • VSTM 11-06-2024
  • Dividend Yield
  • BUJA N/A
  • VSTM N/A
  • EPS Growth
  • BUJA N/A
  • VSTM N/A
  • EPS
  • BUJA 0.29
  • VSTM N/A
  • Revenue
  • BUJA N/A
  • VSTM $10,000,000.00
  • Revenue This Year
  • BUJA N/A
  • VSTM N/A
  • Revenue Next Year
  • BUJA N/A
  • VSTM $125.69
  • P/E Ratio
  • BUJA $37.13
  • VSTM N/A
  • Revenue Growth
  • BUJA N/A
  • VSTM N/A
  • 52 Week Low
  • BUJA $10.30
  • VSTM $2.10
  • 52 Week High
  • BUJA $12.18
  • VSTM $14.22
  • Technical
  • Relative Strength Index (RSI)
  • BUJA 67.66
  • VSTM 63.77
  • Support Level
  • BUJA $10.85
  • VSTM $3.11
  • Resistance Level
  • BUJA $10.85
  • VSTM $3.76
  • Average True Range (ATR)
  • BUJA 0.00
  • VSTM 0.33
  • MACD
  • BUJA -0.00
  • VSTM 0.04
  • Stochastic Oscillator
  • BUJA 87.50
  • VSTM 94.26

About BUJA Bukit Jalil Global Acquisition 1 Ltd.

Bukit Jalil Global Acquisition 1 Ltd is a blank check company.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: